Remove 2027 Remove Competition Remove Side effects
article thumbnail

Novartis takes aim at MS blockbuster Tysabri in US and Europe

pharmaphorum

The looming competition piles further pressure on Biogen, whose MS franchise is already beset by generic competition to oral therapy Tecfidera (dimethyl glutamate), while its attempt to build a market for Alzheimer’s therapy Aduhelm (aducanumab) has ended in failure.

article thumbnail

How to Successfully Market Your GLP-1 Program: Strategies for Standing Out

LEVO Health

billion by 2027. To stand out in this competitive landscape, businesses must focus on patient engagement, comprehensive service offerings, strong marketing and branding, and strategic partnerships with top-tier telehealth service providers like WellSync and medical marketing experts like Levo Health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Top 5 Emerging Trends in Pharma Industry

Medico Reach

The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. billion by 2027. billion in 2022 and will expand at a CAGR of 10.3%

Pharma 52
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro.

Medical 105
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. Results from this trial are scheduled to be released in October 2027, and may allow non-diabetic obese patients to have access to Mounjaro.

Medical 98